A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase I, multicenter, randomized, double‐blind, placebo‐controlled studyevaluating HXN5003 in healthy participants and patients with moderate‐to‐severe atopicdermatitis (AD).The study consists of two parts: Part A (single ascending dose in healthy participants)and Part B (multiple ascending dose in AD patients).The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK),immunogenicity, and preliminary efficacy of HXN5003.
Epistemonikos ID: 51ea8edc778f96eea66efafb2b591b069fe3d158
First added on: Sep 03, 2026